問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Shin Kong Memorial Wu Ho-Su Hospital (在職)

Division of Ophthalmology

更新時間：2023-09-19

高姿芸
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

高姿芸

List

6Cases

2020-08-20 - 2024-08-07

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2021-08-15 - 2026-05-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-05-01 - 2021-08-20

Phase III

To determine if treatment with aflibercept 8 mg (HD) at intervals of 12 or 16 weeks provides non-inferior BCVA change compared to aflibercept 2 mg every 8 weeks in participants with nAMD

  • Condition/Disease

    NAMD

  • Test Drug

    BAY 86-5321

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2021-08-15 - 2024-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2019-08-01 - 2022-03-31

Phase III

A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON)

  • Condition/Disease

    neovascular age-related macular degeneration (TALON)

  • Test Drug

    Brolucizumab (RTH258)

Participate Sites
4Sites

Recruiting4Sites

2021-01-07 - 2023-06-08

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB